These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1453 related items for PubMed ID: 3158551

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
    Baumann R, Kuhl H, Taubert HD, Sandow J.
    Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF, Mishell DR, Stanczyk FZ, Goebelsmann U.
    Am J Obstet Gynecol; 1977 Sep 15; 129(2):133-40. PubMed ID: 900174
    [Abstract] [Full Text] [Related]

  • 12. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K, Lunell NO, Zador G.
    Gynecol Obstet Invest; 1978 Sep 15; 9(6):304-11. PubMed ID: 754992
    [Abstract] [Full Text] [Related]

  • 13. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R, Lähteenmäki P, Luukkainen T, Tuominen J.
    Fertil Steril; 1993 Oct 15; 60(4):610-5. PubMed ID: 8405512
    [Abstract] [Full Text] [Related]

  • 14. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C, Nillius SJ, Wide L, Lindgren A.
    Fertil Steril; 1981 Sep 15; 36(3):339-42. PubMed ID: 6793403
    [Abstract] [Full Text] [Related]

  • 15. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lähteenmäki P.
    Contraception; 1996 Aug 15; 54(2):79-86. PubMed ID: 8842583
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
    Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger U, Walter F, Gräser T.
    Contraception; 1997 Sep 15; 56(3):185-91. PubMed ID: 9347211
    [Abstract] [Full Text] [Related]

  • 18. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ, Dullaart J, Zeilmaker GH.
    J Endocrinol; 1976 Sep 15; 70(3):465-71. PubMed ID: 978105
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O, Gordon K, Williams RF, Hodgen GD.
    Contraception; 1996 Jan 15; 53(1):55-64. PubMed ID: 8631191
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.